is underway to assess safety and tolerability of CEA-targeted CAR therapy for patients with CEA-positive advanced solid tumors such as gastrointestinal (GI) malignancy, lung cancer, and breast cancer (NCT06006390). This evidence concerns the gene CEACAM5 and breast carcinoma.